Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421733 · ClinicalTrials.gov registry record · Phase 2
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
A Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 281
- Enrollment target
- 20
- Study locations
NCT00421733 is a Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy that has completed, run by Abbott. The registered enrollment target is 281 participants, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00421733, a Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 281 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blocker (ARB) therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zemplar (paricalcitol ) capsules
- DRUG Zemplar (paricalcitol) capsules
Study Locations (20)
Florida
- Site Reference ID/Investigator# 853 - Hudson
- Site Reference ID/Investigator# 867 - Lauderdale Lakes
- Site Reference ID/Investigator# 857 - Pembroke Pines
- Site Reference ID/Investigator# 8901 - West Palm Beach
North Carolina
- Site Reference ID/Investigator# 866 - Charlotte
- Site Reference ID/Investigator# 8039 - Greenville
- Site Reference ID/Investigator# 8053 - Morehead City
California
- Site Reference ID/Investigator# 864 - Fountain Valley
- Site Reference ID/Investigator# 7291 - Yuba City
Illinois
- Site Reference ID/Investigator# 2531 - Chicago
- Site Reference ID/Investigator# 3371 - Evanston
Arizona
- Site Reference ID/Investigator# 862 - Phoenix
Georgia
- Site Reference ID/Investigator# 7113 - Roswell
Indiana
- Site Reference ID/Investigator# 869 - Indianapolis
Louisiana
- Site Reference ID/Investigator# 8054 - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421733
The ClinicalTrials.gov registry entry for NCT00421733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00421733 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT00421733 about?
NCT00421733 is a clinical study titled "The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors". The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting enzyme (ACE) inhibitor and/o...
What is the current status of trial NCT00421733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2006-12. Estimated completion is 2009-06.
What conditions does trial NCT00421733 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Diabetic Nephropathy.
What interventions are being tested in trial NCT00421733?
The interventions under investigation include: Placebo (DRUG), Zemplar (paricalcitol ) capsules (DRUG), Zemplar (paricalcitol) capsules (DRUG).
Who is sponsoring clinical trial NCT00421733?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421733 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
RECRUITING · Phase 2
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
RECRUITING · Phase 2
-
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
ACTIVE NOT RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.